The co-founder and CEO of Ritholtz Wealth Management said it’s too soon for investors to extrapolate what could be an idiosyncratic story at Microsoft to the broader tech sector.
Related Posts
Novo Nordisk shares plunge 22% after CagriSema obesity drug trial results
Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 22% on Friday after reporting results in a late-stage trial that missed expectations.
Jeep, Dodge maker Stellantis posts 70% drop in full-year profit
Stellantis on Wednesday reported a sharp drop in full-year earnings as the company scrambles to take measures to improve its performance and profitability.
The new AI rally is leaving Apple behind, at least for now
Apple is struggling in January, while the excitement around Stargate is helping to boost other AI-related stocks.